<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="brief-report"><?DTDIdentifier.IdentifierValue http://null/schema/dtds/document/fulltext/xcr/xocs-article.xsd?><?DTDIdentifier.IdentifierType schema?><?SourceDTD.DTDName xocs-article.xsd?><?SourceDTD.Version 1.0?><?ConverterInfo.XSLTName ftrr2jats.xsl?><?ConverterInfo.Version 1?><?origin publisher?><front><journal-meta><journal-id journal-id-type="nlm-ta">Int J Infect Dis</journal-id><journal-id journal-id-type="iso-abbrev">Int. J. Infect. Dis</journal-id><journal-title-group><journal-title>International Journal of Infectious Diseases</journal-title></journal-title-group><issn pub-type="ppub">1201-9712</issn><issn pub-type="epub">1878-3511</issn><publisher><publisher-name>Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7204704</article-id><article-id pub-id-type="publisher-id">S1201-9712(20)30306-4</article-id><article-id pub-id-type="doi">10.1016/j.ijid.2020.05.001</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Comparison of mortality associated with respiratory viral infections between December 2019 and March 2020 with that of the previous year in Southeastern France</article-title></title-group><contrib-group><contrib contrib-type="author" id="aut0005"><name><surname>Giraud-Gatineau</surname><given-names>Audrey</given-names></name><xref rid="aff0005" ref-type="aff">a</xref><xref rid="aff0010" ref-type="aff">b</xref><xref rid="aff0015" ref-type="aff">c</xref><xref rid="fn0005" ref-type="fn">1</xref></contrib><contrib contrib-type="author" id="aut0010"><name><surname>Colson</surname><given-names>Philippe</given-names></name><xref rid="aff0005" ref-type="aff">a</xref><xref rid="aff0020" ref-type="aff">d</xref><xref rid="fn0005" ref-type="fn">1</xref></contrib><contrib contrib-type="author" id="aut0015"><name><surname>Jimeno</surname><given-names>Marie-Th&#x000e9;r&#x000e8;se</given-names></name><xref rid="aff0025" ref-type="aff">e</xref></contrib><contrib contrib-type="author" id="aut0020"><name><surname>Zandotti</surname><given-names>Christine</given-names></name><xref rid="aff0005" ref-type="aff">a</xref><xref rid="aff0030" ref-type="aff">f</xref></contrib><contrib contrib-type="author" id="aut0025"><name><surname>Ninove</surname><given-names>Laetitia</given-names></name><xref rid="aff0005" ref-type="aff">a</xref><xref rid="aff0030" ref-type="aff">f</xref></contrib><contrib contrib-type="author" id="aut0030"><name><surname>Boschi</surname><given-names>C&#x000e9;line</given-names></name><xref rid="aff0005" ref-type="aff">a</xref><xref rid="aff0020" ref-type="aff">d</xref></contrib><contrib contrib-type="author" id="aut0035"><name><surname>Lagier</surname><given-names>Jean-Christophe</given-names></name><xref rid="aff0005" ref-type="aff">a</xref><xref rid="aff0020" ref-type="aff">d</xref></contrib><contrib contrib-type="author" id="aut0040"><name><surname>La Scola</surname><given-names>Bernard</given-names></name><xref rid="aff0005" ref-type="aff">a</xref><xref rid="aff0020" ref-type="aff">d</xref></contrib><contrib contrib-type="author" id="aut0045"><name><surname>Chaudet</surname><given-names>Herv&#x000e9;</given-names></name><xref rid="aff0005" ref-type="aff">a</xref><xref rid="aff0010" ref-type="aff">b</xref><xref rid="aff0015" ref-type="aff">c</xref></contrib><contrib contrib-type="author" id="aut0050"><name><surname>Raoult</surname><given-names>Didier</given-names></name><email>didier.raoult@gmail.com</email><xref rid="aff0005" ref-type="aff">a</xref><xref rid="aff0020" ref-type="aff">d</xref><xref rid="cor0005" ref-type="corresp">&#x0204e;</xref></contrib><aff id="aff0005"><label>a</label>IHU M&#x000e9;diterran&#x000e9;e Infection, Marseille, France</aff><aff id="aff0010"><label>b</label>Aix Marseille Univ, Institut de Recherche pour le D&#x000e9;veloppement (IRD), Assistance Publique - H&#x000f4;pitaux de Marseille (AP-HM), Service de Sant&#x000e9; des Arm&#x000e9;es (SSA), Vecteurs - Infections Tropicales et M&#x000e9;diterran&#x000e9;ennes (VITROME), Marseille, France</aff><aff id="aff0015"><label>c</label>French Armed Forces Center for Epidemiology and Public Health (CESPA), Service de Sant&#x000e9; des Arm&#x000e9;es (SSA), Marseille, France</aff><aff id="aff0020"><label>d</label>Aix-Marseille Univ., Institut de Recherche pour le D&#x000e9;veloppement (IRD), Assistance Publique - H&#x000f4;pitaux de Marseille (AP-HM), Microbes Evolution Phylogeny and Infections (MEPHI), Marseille, France</aff><aff id="aff0025"><label>e</label>Service de l&#x02019;Information M&#x000e9;dicale, H&#x000f4;pital de la Timone, Marseille, France</aff><aff id="aff0030"><label>f</label>Unit&#x000e9; des Virus Emergents (UVE), Aix-Marseille University, IRD 190, Inserm 1207, IHU M&#x000e9;diterran&#x000e9;e Infection, Marseille, France</aff></contrib-group><author-notes><corresp id="cor0005"><label>&#x0204e;</label>Corresponding author at: IHU M&#x000e9;diterran&#x000e9;e Infection, 19-21 boulevard Jean Moulin, 13005 Marseille, France. <email>didier.raoult@gmail.com</email></corresp><fn id="fn0005"><label>1</label><p id="npar0010">Contributed equally.</p></fn></author-notes><pub-date pub-type="pmc-release"><day>7</day><month>5</month><year>2020</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.--><pub-date pub-type="ppub"><month>7</month><year>2020</year></pub-date><pub-date pub-type="epub"><day>7</day><month>5</month><year>2020</year></pub-date><volume>96</volume><fpage>154</fpage><lpage>156</lpage><history><date date-type="received"><day>29</day><month>3</month><year>2020</year></date><date date-type="rev-recd"><day>25</day><month>4</month><year>2020</year></date><date date-type="accepted"><day>1</day><month>5</month><year>2020</year></date></history><permissions><copyright-statement>&#x000a9; 2020 Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.</copyright-statement><copyright-year>2020</copyright-year><copyright-holder/><license><license-p>Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.</license-p></license></permissions><abstract abstract-type="author-highlights" id="abs0005"><title>Highlights</title><p><list list-type="simple" id="lis0005"><list-item id="lsti0005"><label>&#x02022;</label><p id="par0005">There were fewer common respiratory virus-associated deaths in Southeastern France hospitals during 2019&#x02013;2020 vs 2018&#x02013;2019.</p></list-item><list-item id="lsti0010"><label>&#x02022;</label><p id="par0010">The majority were due to decreases in influenza A virus and respiratory syncytial virus (RSV)-associated deaths.</p></list-item><list-item id="lsti0015"><label>&#x02022;</label><p id="par0015">55 deaths were associated with a SARS-CoV-2 diagnosis.</p></list-item><list-item id="lsti0020"><label>&#x02022;</label><p id="par0020">There was similar respiratory virus-associated mortality among hospitalized patients.</p></list-item><list-item id="lsti0025"><label>&#x02022;</label><p id="par0025">SARS-CoV-2 infections had a limited impact on the number of deaths of any cause among hospitalized people.</p></list-item></list></p></abstract><abstract id="abs0010"><p>Respiratory viruses are a major cause of mortality worldwide and in France, where they cause several thousands of deaths every year. University Hospital Institute-M&#x000e9;diterran&#x000e9;e Infection performs real-time surveillance of all diagnoses of infections and associated deaths in public hospitals in Marseille, Southeastern France. This study compared mortality associated with diagnoses of respiratory viruses during the colder months of 2018&#x02013;2019 and 2019&#x02013;2020 (week 47&#x02013;week 14). In 2018&#x02013;2019, 73 patients (0.17% of 42,851 hospitalized patients) died after being diagnosed with a respiratory virus; 40 and 13 deaths occurred in patients diagnosed with influenza A virus and respiratory syncytial virus (RSV), respectively. In 2019&#x02013;2020, 50 patients (0.10% of 49,043 patients hospitalized) died after being diagnosed with a common respiratory virus; seven and seven deaths occurred in patients diagnosed with influenza A virus and RSV, respectively. Additionally, 55 patients died after being diagnosed with SARS-CoV-2. The proportion of respiratory virus-associated deaths among hospitalized patients was thus significantly lower for common respiratory viruses in 2019&#x02013;2020 than in 2018&#x02013;2019 (102 versus 170 per 100,000 hospitalized patients; <italic>p</italic> = 0.003), primarily as a consequence of a decrease in influenza A virus (&#x02013;83%) and RSV (&#x02013;46%)-associated deaths. Overall, the proportion of respiratory virus-associated deaths among hospitalized patients was higher, but not significantly, in 2019&#x02013;2020 than in 2018&#x02013;2019 (214 versus 170 per 100,000 hospitalized patients; <italic>p</italic> = 0.08, Yates-corrected Chi-square test). These findings put into perspective the death burden of SARS-CoV-2 infections in this geographical area.</p></abstract><kwd-group id="kwd0005"><title>Keywords</title><kwd>Respiratory viruses</kwd><kwd>Mortality</kwd><kwd>Influenza virus</kwd><kwd>SARS-CoV-2</kwd><kwd>France</kwd></kwd-group></article-meta></front><body><p id="par0030">Respiratory viruses are a major cause of mortality worldwide, with an estimated 2.7 million deaths in 2015 (<xref rid="bib0015" ref-type="bibr">GBD 2015 LRI Collaborators, 2017</xref>). In France, they cause several thousands of deaths every year during the colder months (<xref rid="bib0030" ref-type="bibr">Pivette et al., 2020</xref>). Since January 2020, the SARS-CoV-2 outbreak has generated much fear and countermeasures to stem the spread of this respiratory virus. This has largely been fueled by the tremendously extensive reporting of Covid-19-associated deaths. As of 31 March 2020, 770,520 people have been found infected worldwide, of whom 36,942 (4.8%) died. Five countries (Italy, Spain, China, USA and France) have been affected by 77% of these deaths (<ext-link ext-link-type="uri" xlink:href="https://coronavirus.jhu.edu/map.html" id="intr0010">https://coronavirus.jhu.edu/map.html</ext-link>). France identified 3,024 deaths for 44,450 infections (6.8%). The University Hospital Institute M&#x000e9;diterran&#x000e9;e Infection performs, with in-house tools, a real-time surveillance of all infections in public hospitals in Marseille, Southeastern France (<xref rid="bib0005" ref-type="bibr">Abat et al., 2015</xref>, <xref rid="bib0035" ref-type="bibr">Roussel et al., 2020</xref>). This surveillance allows weekly analysis of the numbers of each type of clinical sample received and any pathogen diagnosed at the laboratory, including respiratory samples and viruses, and performing retrospective analyses that include the most recently available data. It also includes the count of the deaths associated with any diagnosed infection. This study compared the mortality associated with diagnoses of respiratory viruses during the colder months overlapping 2018&#x02013;2019 and 2019&#x02013;2020.</p><p id="par0035">Testing of respiratory samples was performed using FTD Respiratory pathogens 21 (Fast Track Diagnosis, Luxembourg) or Biofire FilmArray Respiratory panel 2 plus (Biom&#x000e9;rieux, France) assays. Between week 47 of 2018 and week 14 of 2019, 73 patients died after being diagnosed with respiratory viruses (<xref rid="tbl0005" ref-type="table">Table 1</xref>
). They represented 0.17% of the 42,851 patients hospitalized during this period and 6.3% of the 1,137 who died. Deaths occurred in 40 of the patients diagnosed with influenza A virus (1.7%), which was the respiratory virus associated with the highest number of deaths. In addition, deaths occurred in 19 of the patients diagnosed with rhinoviruses (1.5%), and in 13 of those diagnosed with respiratory syncytial virus (RSV) (1.1%). Respiratory samples had not been tested for coronaviruses and parainfluenza viruses in routine clinical practice, but all those retrospectively tested from patients who died in Marseille public hospitals were negative. In comparison, during the same period of winter 2019&#x02013;2020 (between week 47 of 2019 and week 14 of 2020), 50 patients died after being diagnosed with a common respiratory virus. They represented 0.10% of the 49,043 patients hospitalized during this period and 4.5% of the 1,115 who died. They included seven of the patients diagnosed with influenza A virus (0.5%), three of those diagnosed with influenza B virus (0.2%), seven of those diagnosed with RSV (0.7%), and six, two and one of those diagnosed with human coronavirus-HKU1 (2.4%), NL63 (1.2%) and OC43 (0.8%), respectively (<xref rid="tbl0005" ref-type="table">Table 1</xref>). Additionally, since the 29 January 2020, 25,786 patients were tested for SARS-CoV-2 using a reverse transcription-PCR assay (<xref rid="bib0010" ref-type="bibr">Amrane et al., 2020</xref>), and 3,587 infections were diagnosed positive (13.9%). Of these infected patients, 55 (1.5%) died; their median age was 82 years.<table-wrap position="float" id="tbl0005"><label>Table 1</label><caption><p>Tests performed and positive for PCR detection of respiratory viruses, and associated deaths during the same colder months overlapping the years 2018&#x02013;2019 and 2019&#x02013;2020.</p></caption><alt-text id="at0020">Table 1</alt-text><table frame="hsides" rules="groups"><thead><tr><th align="left">Viruses</th><th colspan="2" align="left">Tests<hr/></th><th colspan="4" align="left">Positive patients<hr/></th><th colspan="4" align="left">Deaths<hr/></th><th align="left"><italic>P</italic><xref rid="tblfn0005" ref-type="table-fn">a</xref></th></tr><tr><th align="left"/><th align="left">2018&#x02013;2019</th><th align="left">2019&#x02013;2020</th><th colspan="2" align="left">2018&#x02013;2019<hr/></th><th colspan="2" align="left">2019&#x02013;2020<hr/></th><th colspan="2" align="left">2018&#x02013;2019<hr/></th><th colspan="2" align="left">2019&#x02013;2020<hr/></th><th align="left"/></tr><tr><th align="left"/><th align="left">Number</th><th align="left">Number</th><th align="left">Number</th><th align="left"><italic>%</italic></th><th align="left">Number</th><th align="left"><italic>%</italic></th><th align="left">Number</th><th align="left">%</th><th align="left">Number</th><th align="left"><italic>%</italic></th><th align="left"/></tr></thead><tbody><tr><td align="left">Adenovirus</td><td align="left">11,922</td><td align="left">16,098</td><td align="left">475</td><td align="left"><italic>4.0</italic></td><td align="left">448</td><td align="left"><italic>2.8</italic></td><td align="left">2</td><td align="left"><italic>0.4</italic></td><td align="left">4</td><td align="left"><italic>0.9</italic></td><td align="left"/></tr><tr><td align="left">Coronavirus HKU1</td><td align="left">&#x02013;</td><td align="left">10,097</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">253</td><td align="left"><italic>2.5</italic></td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">6</td><td align="left"><italic>2.4</italic></td><td align="left"/></tr><tr><td align="left">Coronavirus NL63</td><td align="left">&#x02013;</td><td align="left">10,097</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">173</td><td align="left"><italic>1.7</italic></td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">2</td><td align="left"><italic>1.2</italic></td><td align="left"/></tr><tr><td align="left">Coronavirus OC43</td><td align="left">&#x02013;</td><td align="left">10,097</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">120</td><td align="left"><italic>1.2</italic></td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">1</td><td align="left"><italic>0.8</italic></td><td align="left"/></tr><tr><td align="left">Coronavirus E229</td><td align="left">&#x02013;</td><td align="left">10,097</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">69</td><td align="left"><italic>0.7</italic></td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">0</td><td align="left"><italic>0.0</italic></td><td align="left"/></tr><tr><td align="left">SARS-CoV-2</td><td align="left">&#x02013;</td><td align="left">42,242</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">3,587</td><td align="left"><italic>8.5</italic></td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">55</td><td align="left"><italic>1.5</italic></td><td align="left"/></tr><tr><td align="left">Enterovirus</td><td align="left">11,922</td><td align="left">16,098</td><td align="left">343</td><td align="left"><italic>2.9</italic></td><td align="left">362</td><td align="left"><italic>2.3</italic></td><td align="left">1</td><td align="left"><italic>0.3</italic></td><td align="left">2</td><td align="left"><italic>0.6</italic></td><td align="left"/></tr><tr><td align="left">Influenza A virus</td><td align="left">11,922</td><td align="left">16,098</td><td align="left">2,293</td><td align="left"><italic>19.2</italic></td><td align="left">1,554</td><td align="left"><italic>9.7</italic></td><td align="left">40</td><td align="left"><italic>1.7</italic></td><td align="left">7</td><td align="left"><italic>0.5</italic></td><td align="left"><italic>&#x0003c;0.001</italic></td></tr><tr><td align="left">Influenza B virus</td><td align="left">11,922</td><td align="left">16,098</td><td align="left">15</td><td align="left"><italic>0.1</italic></td><td align="left">1,261</td><td align="left"><italic>7.8</italic></td><td align="left">0</td><td align="left"><italic>0.0</italic></td><td align="left">3</td><td align="left"><italic>0.2</italic></td><td align="left"/></tr><tr><td align="left">Metapneumovirus</td><td align="left">11,922</td><td align="left">16,098</td><td align="left">346</td><td align="left"><italic>2.9</italic></td><td align="left">472</td><td align="left"><italic>2.9</italic></td><td align="left">0</td><td align="left"><italic>0.0</italic></td><td align="left">5</td><td align="left"><italic>1.1</italic></td><td align="left"/></tr><tr><td align="left">Parainfluenza virus 1</td><td align="left">&#x02013;</td><td align="left">10,097</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">7</td><td align="left"><italic>0.1</italic></td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">0</td><td align="left"><italic>0.0</italic></td><td align="left"/></tr><tr><td align="left">Parainfluenza virus 2</td><td align="left">&#x02013;</td><td align="left">10,097</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">12</td><td align="left"><italic>0.1</italic></td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">0</td><td align="left"><italic>0.0</italic></td><td align="left"/></tr><tr><td align="left">Parainfluenza virus 3</td><td align="left">&#x02013;</td><td align="left">10,097</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">11</td><td align="left"><italic>0.1</italic></td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">0</td><td align="left"><italic>0.0</italic></td><td align="left"/></tr><tr><td align="left">Parainfluenza virus 4</td><td align="left">&#x02013;</td><td align="left">10,097</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">30</td><td align="left"><italic>0.3</italic></td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">0</td><td align="left"><italic>0.0</italic></td><td align="left"/></tr><tr><td align="left">Rhinovirus</td><td align="left">11,922</td><td align="left">16,098</td><td align="left">1,241</td><td align="left"><italic>10.4</italic></td><td align="left">1,565</td><td align="left"><italic>9.7</italic></td><td align="left">19</td><td align="left"><italic>1.5</italic></td><td align="left">15</td><td align="left"><italic>1.0</italic></td><td align="left"><italic>0.11</italic></td></tr><tr><td align="left">Syncytial respiratory virus</td><td align="left">11,922</td><td align="left">16,098</td><td align="left">1,146</td><td align="left"><italic>9.6</italic></td><td align="left">1,044</td><td align="left"><italic>6.5</italic></td><td align="left">13</td><td align="left"><italic>1.1</italic></td><td align="left">7</td><td align="left"><italic>0.7</italic></td><td align="left"><italic>0.18</italic></td></tr></tbody></table><table-wrap-foot><fn id="tblfn0005"><label>a</label><p id="npar0005">Assessed for proportions of deaths among positive patients; Yates-corrected Chi-square test.</p></fn></table-wrap-foot></table-wrap></p><p id="par0040">Thus, a total of 105 patients died after being diagnosed with a respiratory virus during the colder months of 2019&#x02013;2020 until week 14 of 2020 compared with 73 the year before during the same timeframe (+44%). However, the proportion of respiratory virus-associated deaths among hospitalized patients did not significantly differ in 2019&#x02013;2020 and 2018&#x02013;2019 (214 versus 170 per 100,000 hospitalized patients; <italic>p</italic> = 0.08, Yates-corrected Chi-square test). In contrast, it was significantly lower in 2019&#x02013;2020 than in 2018&#x02013;2019 for common respiratory viruses (102 versus 170 per 100,000 hospitalized patients; <italic>p</italic> = 0.003), which were associated with 33% fewer deaths in 2019&#x02013;2020. This drop was essentially due to a significant decrease in influenza A virus-associated deaths (&#x02013;84%; <italic>p</italic> &#x0003c;0.001) and a decrease in RSV-associated deaths (-46%; <italic>p</italic> = 0.18)among patients diagnosed with these viruses. The drop in influenza-associated deaths could be partly explained by the predominance of A/H3N2 strains in 2018&#x02013;2019 compared with the predominance of A/H1N1 and B strains in 2019&#x02013;2020, as A/H3N2 strains were reported to be associated with a greater mortality in elderly people (<xref rid="bib0020" ref-type="bibr">Lemaitre et al., 2012</xref>, <xref rid="bib0025" ref-type="bibr">Paget et al., 2019</xref>). A 21% drop in the number of deaths in patients diagnosed with rhinovirus, and a reduction from 1.5% to 1% of the proportion of deaths among diagnosed patients (<italic>p</italic> = 0.11) was also observed in 2019&#x02013;2020 compared with 2018&#x02013;2019.</p><p id="par0045">Overall, these findings put into perspective the death burden of SARS-CoV-2 infections in this geographical area. Thus, the number of SARS-CoV-2-associated deaths was similar to that of deaths associated with other viral respiratory infections between December 2019 and March 2020, and lower than that of deaths associated with viral respiratory infections between December 2018 and March 2019. In addition, no significant impact of SARS-CoV-2 infections was observed on the overall number of deaths (of any cause) among hospitalized people in Marseille public hospitals (1,115 deaths in 2019&#x02013;2020 during the study period versus 1,137 in 2018&#x02013;2019; <xref rid="fig0005" ref-type="fig">Figure 1</xref>
a), or in the population of metropolitan France (175,384 deaths in 2019&#x02013;2020 versus 173,923 in 2018&#x02013;2019; <xref rid="fig0005" ref-type="fig">Figure 1</xref>b; <ext-link ext-link-type="uri" xlink:href="https://www.insee.fr/fr/statistiques/serie/000436394#Telechargement" id="intr0015">https://www.insee.fr/fr/statistiques/serie/000436394#Telechargement</ext-link>). Further analyses might determine if this is related to containment or other changes related to the SARS-CoV-2 epidemics. The number of SARS-CoV-2-associated deaths will grow after the timeframe of the present study as a consequence of recent or new infections, but the peak of incidence of SARS-CoV-2 infections was reached at the end of March 2020 in Marseille public hospitals (<ext-link ext-link-type="uri" xlink:href="https://www.mediterranee-infection.com/covid-19/" id="intr0020">https://www.mediterranee-infection.com/covid-19/</ext-link>) and in metropolitan France (<ext-link ext-link-type="uri" xlink:href="https://www.santepubliquefrance.fr/content/download/246357/2578114" id="intr0025">https://www.santepubliquefrance.fr/content/download/246357/2578114</ext-link>).<fig id="fig0005"><label>Figure 1</label><caption><p>Number of deaths of any cause per month in Marseille public hospitals (a) and in Metropolitan France (<ext-link ext-link-type="uri" xlink:href="https://www.insee.fr/fr/statistiques/serie/000436394#Telechargement" id="intr0005">https://www.insee.fr/fr/statistiques/serie/000436394#Telechargement</ext-link>) (b).</p><p>Periods of time analysed in the present study are indicated by the rectangles with a grey background.</p></caption><alt-text id="at0015">Figure 1</alt-text><graphic xlink:href="gr1_lrg"/></fig></p><sec id="sec0005"><title>Author contributions</title><p id="par0050">Conceived and designed the study: DR. Contributed materials/analysis tools: AG, PC, MTJ, CZ, LN, CB, JCL, BLS, HC. Analyzed the data: AG, PC, DR. Wrote the paper: AG, PC, DR.</p></sec><sec id="sec0010"><title>Funding</title><p id="par0055">This work was supported by the <funding-source id="gs0005">French Government</funding-source>under the &#x0201c;Investments for the Future&#x0201d; program managed by the <funding-source id="gs0010">National Agency for Research</funding-source> (ANR) (No. <funding-source id="gs0015">M&#x000e9;diterran&#x000e9;e-Infection</funding-source>10-IAHU-03) and was also supported by <funding-source id="gs0020">R&#x000e9;gion Provence-Alpes-C&#x000f4;te d&#x02019;Azur</funding-source> and European funding FEDER PRIMMI (<funding-source id="gs0025">Fonds Europ&#x000e9;en de D&#x000e9;veloppement R&#x000e9;gional - Plateformes de Recherche et d'Innovation Mutualis&#x000e9;es M&#x000e9;diterran&#x000e9;e Infection</funding-source>).</p></sec><sec id="sec0015"><title>Conflicts of interest</title><p id="par0060">The authors have no conflicts of interest to declare. Funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript.</p></sec><sec id="sec0020"><title>Ethical approval</title><p id="par0065">Not required. All data have been generated as part of the routine work at Assistance Publique-H&#x000f4;pitaux de Marseille (Marseille university hospitals), and this study results from routine standard clinical management.</p></sec></body><back><ref-list id="bibl0005"><title>References</title><ref id="bib0005"><element-citation publication-type="journal" id="sbref0005"><person-group person-group-type="author"><name><surname>Abat</surname><given-names>C.</given-names></name><name><surname>Chaudet</surname><given-names>H.</given-names></name><name><surname>Colson</surname><given-names>P.</given-names></name><name><surname>Rolain</surname><given-names>J.M.</given-names></name><name><surname>Raoult</surname><given-names>D.</given-names></name></person-group><article-title>Real-time microbiology laboratory surveillance system to detect abnormal events and emerging infections, Marseille, France</article-title><source>Emerg Infect Dis</source><volume>21</volume><year>2015</year><fpage>1302</fpage><lpage>1310</lpage><pub-id pub-id-type="pmid">26196165</pub-id></element-citation></ref><ref id="bib0010"><element-citation publication-type="journal" id="sbref0010"><person-group person-group-type="author"><name><surname>Amrane</surname><given-names>S.</given-names></name><name><surname>Tissot-Dupont</surname><given-names>H.</given-names></name><name><surname>Doudier</surname><given-names>B.</given-names></name><name><surname>Eldin</surname><given-names>C.</given-names></name><name><surname>Hocquart</surname><given-names>M.</given-names></name><name><surname>Mailhe</surname><given-names>M.</given-names></name></person-group><article-title>Rapid viral diagnosis and ambulatory management of suspected COVID-19 cases presenting at the infectious diseases referral hospital in Marseille, France, - January 31st to March 1st, 2020: a respiratory virus snapshot</article-title><source>Travel Med Infect Dis</source><year>2020</year><fpage>101632</fpage><pub-id pub-id-type="pmid">32205269</pub-id></element-citation></ref><ref id="bib0015"><element-citation publication-type="journal" id="sbref0015"><person-group person-group-type="author"><name><surname>GBD 2015 LRI Collaborators</surname></name></person-group><article-title>Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory tract infections in 195 countries: a systematic analysis for the Global Burden of Disease Study 2015</article-title><source>Lancet Infect Dis</source><volume>17</volume><year>2017</year><fpage>1133</fpage><lpage>1161</lpage><pub-id pub-id-type="pmid">28843578</pub-id></element-citation></ref><ref id="bib0020"><element-citation publication-type="journal" id="sbref0020"><person-group person-group-type="author"><name><surname>Lemaitre</surname><given-names>M.</given-names></name><name><surname>Carrat</surname><given-names>F.</given-names></name><name><surname>Rey</surname><given-names>G.</given-names></name><name><surname>Miller</surname><given-names>M.</given-names></name><name><surname>Simonsen</surname><given-names>L.</given-names></name><name><surname>Viboud</surname><given-names>C.</given-names></name></person-group><article-title>Mortality burden of the 2009 A/H1N1 influenza pandemic in France: comparison to seasonal influenza and the A/H3N2 pandemic</article-title><source>PLoS One</source><volume>7</volume><year>2012</year><object-id pub-id-type="publisher-id">e45051</object-id></element-citation></ref><ref id="bib0025"><element-citation publication-type="journal" id="sbref0025"><person-group person-group-type="author"><name><surname>Paget</surname><given-names>J.</given-names></name><name><surname>Spreeuwenberg</surname><given-names>P.</given-names></name><name><surname>Charu</surname><given-names>V.</given-names></name><name><surname>Taylor</surname><given-names>R.J.</given-names></name><name><surname>Iuliano</surname><given-names>A.D.</given-names></name><name><surname>Bresee</surname><given-names>J.</given-names></name></person-group><article-title>Global mortality associated with seasonal influenza epidemics: new burden estimates and predictors from the GLaMOR Project</article-title><source>J Glob Health</source><volume>9</volume><year>2019</year><object-id pub-id-type="publisher-id">020421</object-id></element-citation></ref><ref id="bib0030"><element-citation publication-type="journal" id="sbref0030"><person-group person-group-type="author"><name><surname>Pivette</surname><given-names>M.</given-names></name><name><surname>Nicolay</surname><given-names>N de L V</given-names></name><name><surname>Hubert</surname><given-names>B.</given-names></name></person-group><article-title>Characteristics of hospitalizations with an influenza diagnosis, France, 2012&#x02013;2013 to 2016&#x02013;2017 influenza seasons</article-title><source>Influenza Other Respir Viruses</source><issue>February</issue><year>2020</year><pub-id pub-id-type="doi">10.1111/irv.12719</pub-id><comment>[Epub ahead of print]</comment></element-citation></ref><ref id="bib0035"><element-citation publication-type="journal" id="sbref0035"><person-group person-group-type="author"><name><surname>Roussel</surname><given-names>Y.</given-names></name><name><surname>Giraud-Gatineau</surname><given-names>A.</given-names></name><name><surname>Jimeno</surname><given-names>M.T.</given-names></name><name><surname>Rolain</surname><given-names>J.M.</given-names></name><name><surname>Zandotti</surname><given-names>C.</given-names></name><name><surname>Colson</surname><given-names>P.</given-names></name></person-group><article-title>SARS-CoV-2: fear versus data</article-title><source>Int J Antimicrob Agents</source><year>2020</year><fpage>105947</fpage><pub-id pub-id-type="pmid">32201354</pub-id></element-citation></ref></ref-list><ack id="ack0005"><title>Acknowledgments</title><p>We are grateful to the reviewers for the valuable comments that improved this manuscript.</p></ack></back></article>